AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
The rise of central nervous system technologies: Trends reshaping CNS care
This article, co-authored by CRA’s Will Foster and Juliette Richards, explores how advances in artificial intelligence (AI), data collection, and connected...